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Abstract Novel strategies are needed to further reduce the
burden of cytomegalovirus (CMV) disease in solid-organ trans-
plant (SOT) recipients. Measurement of the specific cell-
mediated immunity against CMV can identify the actual risk
for the development of CMV disease in a given patient. Thus,
immune monitoring is an attractive strategy for individualizing
the management of CMV after transplantation. A growing
number of observational studies on immune monitoring for
CMV have been published over recent years, although there
is a lack of data coming from interventional trials. In high-risk
patients, measurement of CMV-specific T-cell responses appro-
priately stratifies the risk of CMV disease after discontinuation
of antiviral prophylaxis. Immune monitoring may also help to
identify patients followed by the preemptive approach at low
risk for progression to CMV disease. Pretransplant assessment
of cell-mediated immunity in seropositive patients may predict
the development of posttransplant CMV infection. Overall,
these studies indicate that the use of cell-mediated immunity
assays has the potential to improve the management of CMV
disease in SOT recipients.
Keywords Cell-mediated immunity . Quantiferon-CMV .
ELISPOT . Prevention
Introduction
Cytomegalovirus (CMV) is considered the number one viral
pathogen after organ transplantation [1••, 2]. CMV disease has
been associated with significant morbidity and even mortality
in solid-organ transplant (SOT) recipients [3]. However, over
the last decade, major improvements in the prevention and
management of CMV disease have been achieved, due to the
introduction of universal antiviral strategies after transplanta-
tion [4, 5]. Currently, overall incidence of CMV disease is
below 10 % in some transplant programs [6, 7], and when
occurring, CMV disease is usually managed on an outpatient
basis using oral antiviral drugs. Despite these improvements,
the prevention of CMV remains challenging. In the subgroup
of patients at high risk (the seronegative recipient of an organ
from a seropositive donor, [D+/R−]), incidence of CMVdisease
may be as high as 30%–40% [8]; thus, a better identification of
the actual risk for developing CMV would be useful for indi-
vidualizing the management of CMV. On the contrary, patients
at very low risk for CMVmay benefit fromminimal preventive
strategies, thus reducing costs and the toxicity associated with
the use of antiviral drugs [9].
Because cell-mediated immunity is known to be the key
player in controlling CMV replication after transplantation,
measurement of the specific T-cell response against CMV
may stratify patients according to the individual risk for
developing CMV disease. I review here the recent literature
on the clinical application of immune monitoring for CMV
for improving the preventive strategies against CMV disease
after transplantation.
Cell-Mediated Immunity Assays
The adaptive immune system, and particularly T-cell immu-
nity, plays an important role in the immunological control of
CMV in SOT recipients. The mechanisms involved in the
cellular immune response to CMV after transplantation have
been recently reviewed elsewhere [10, 11]. Both CD8+ and
CD4+ T-cells participate in the immune response to CMV.
CD8+ T-cells are mainly involved early after transplantation
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and are necessary to establish an immune response following
primary infection, while CD4+ T-cells seem to be more
implicated in establishing a long-term immune control against
CMV [11]. Recent studies have also evaluated the antiviral
role of other lymphocyte subpopulations, such as Treg, Th17,
and γ-δ T-cells [12, 13].
Several assays are available for the measurement of CMV-
specific cell-mediated immunity. Most of these tests rely on
the detection of interferon-γ after in vitro stimulation of
T-cells with CMV peptides or infected cell lysates. Importantly,
over the last few years, some standardized commercial assays
have become available, which is an essential requirement for
including these assays in the research agenda and, eventually,
in the routine clinical practice.
The Quantiferon-CMV assay (Cellestis, Australia) is an
ELISA-based assay that detects the release of interferon-γ
after in vitro stimulation in whole blood by a pool of HLA-
restricted CMV epitopes [14]. The assay consists of three
tubes: a CMV tube coated with the CMVepitopes, a mitogen
tube with phytohemagglutinine used as a positive control, and
a nil tube used as a negative control [15]. A positive result of
the assay requires a detectable release of interferon-γ from
the CMV tube. Most of the studies have used a cutoff for
positivity of >0.2 IU/ml, although in D+/R− patients, a
cutoff of >0.1 IU/ml increases sensitivity and, therefore,
seems to be more appropriate [15, 16]. An indeterminate
result is given when both the CMV tube and the mitogen
tube are nonreactive, and this has been related to anergy
(usually following the use of T-cell-depleting agents) [17•].
In healthy volunteers, the Quantiferon-CMV correlates well
with the CMV serostatus, although in immunocompromised
patients, a significant number of seropositive patients may not
have a detectable cell-mediated response by the Quantiferon-
CMVassay [18]. In a study involving hematopoietic stem cell
transplant (HSCT) recipients, the Quantiferon-CMV assay
appropriately correlated with polyfunctional CMV-specific
CD8+ T-cell responses [19]. The Quantiferon-CMV assay is
CE approved.
The ELISPOT assay detects the release of interferon-γ by
CD4+ and CD8+ T-cells after stimulation of peripheral blood
mononuclear cells (PBMCs) by CMVantigens (CMV-specific
T-cell epitopes or whole infected cell lysates) [10]. Most
studies have used a home-made assay for the evaluation of
the T-cell response; thus, comparison of results between
studies is difficult [20–22]. Of note, the technique of the
ELISPOT is cumbersome, especially as compared with the
Quantiferon-CMV assay. A commercial ELISPOT is CE
approved (T-Track CMV, Lophius, Germany), but experience in
its use in SOT recipients is limited. There is no standard cutoff
for positivity of the ELISPOT assay, although it is generally
accepted that a cutoff from 5 to 50 spot-forming cells (SFCs)
defines a detectable T-cell response [20]. A recent study com-
paring the Quantiferon-CMV assay and an ELISPOT-CMV
assay in kidney transplant recipients found that a cutoff above
150 SFCs/200,000 PBMCs of the ELISPOT was associated
with protection from CMV infection [23].
Intracellular cytokine staining (ICS) detects interferon-γ and
other cytokines by flow cytometry.Whole blood or PBMCs are
stimulated with CMV peptides/lysate. Of note, staining of
stimulated PBMCs allows not only quantification, but also the
characterization of CMV-specific CD4+ and CD8+ T-cells;
therefore, a more accurate assessment of the specific cell-
mediated immunity is obtained using ICS [24–27]. A disad-
vantage of this assay is the need for a flow cytometer, so that it
is difficult to implement outside a research laboratory.
A new commercial assay named Dextramer® CMV Kit
(Immudex, Denmark) contains a dextran polymer carrying
multiple MHC-CMV peptide complexes. The CMV dextramer
recognizes CMV-specific T-cell receptors on the surface of
CD8+ T cells and can detect and quantify CMV-specific
T-cells by flow cytometry. Experience with this assay is
limited so far to HSCT recipients.
Current Challenges in the Prevention of CMV Disease
in SOT Recipients
Two main strategies are currently used for the prevention of
CMV in SOT recipients—namely, antiviral prophylaxis and
preemptive therapy [2]. Prophylaxis relies on the administra-
tion of an antiviral drug during the period of highest risk for
CMV—that is, 3–6 months posttransplant. The preemptive
approach consists in monitoring the CMV viral load and in
starting antiviral therapy once viremia is detected, before the
development of symptoms. The choice of each strategy is
generally determined at the time of transplantation by the
estimated risk for developing CMV disease. D+/R− patients
generally receive antiviral prophylaxis, while seropositive
(R+) recipients can be managed by either the preemptive
approach or prophylaxis [28]. In addition, patients who receive
T-cell-depleting antibodies as induction therapy or therapy for
rejection are considered at high risk and, therefore, more
commonly receive antiviral prophylaxis [1••, 2].
Late-onset CMV disease refers to the development of
CMV disease after the discontinuation of antiviral prophylaxis
[29]. While this is quite uncommon in CMV R+ patients
(usually less than 5 %) [6], late-onset CMV disease incidence
may reach up to 30 %–40 % in high-risk D+/R− patients in
some series [8, 30, 31]. There is no consensus in the literature as
to whether late-onset CMV disease is associated with impaired
transplant outcomes, since it was shown for early-onset CMV
disease before the introduction of universal preventive strate-
gies [3]. Some studies found that patients with late-onset CMV
disease had a higher incidence of graft loss and even all-causes
mortality [32, 33], while some recent prospective cohorts did
not confirm these results [6, 34]. Extending the duration of
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antiviral prophylaxis to 6 or 12 months (depending on the type
of organ) further reduces CMV disease incidence, but at some
cost [8, 30]. Monitoring of CMV viral load after discontinua-
tion of antiviral prophylaxis (i.e., a hybrid approach) may
identify patients with asymptomatic viremia at risk for subse-
quently developing CMV disease. However, this is difficult to
implement, and it is not currently recommended in the routine
clinical practice [35, 36].
In patients at intermediate risk for the development of
CMV disease, the standard duration of 3 months of antiviral
prophylaxis may be associated with some toxicity [9]. Even if
followed by the preemptive approach, some patients with
asymptomatic viremia may not subsequently develop CMV
disease if untreated, since the recipient immune response may
spontaneously control CMV viremia [37]. Therefore, identi-
fication of patients at very low risk for the development of
CMV disease may reduce the administration of antiviral drugs
(either prophylactically or preemptively) and, therefore, avoid
their overuse.
Clinical Experience with Immune Monitoring
in the Prevention of CMV Disease
Since a detectable specific T-cell response against CMV is
correlated with an appropriate immune control of CMVof the
recipient [10], the monitoring of cell-mediated immunity may
be useful in establishing the real risk for developing CMV
disease after transplantation and, therefore, for individualizing
preventive strategies accordingly. The clinical experience
with the use of immune monitoring for CMV is still limited,
although a growing number of articles have been published
over recent years. Importantly, the cell-mediated immune assays
have been assessed in different clinical scenarios, including
SOT recipients both at high-risk and at low risk for developing
CMV disease after discontinuation of antiviral prophylaxis
and patients managed by preemptive therapy. This growing
knowledge is essential to delineating the most cost-effective
strategies for integrating immunemonitoring in the prevention
of CMV disease. Table 1 shows the potential clinical scenarios
for the use of cell-mediated immune assays in the prevention
of CMV disease.
Predicting Late-Onset CMV Disease After Discontinuation
of Antiviral Prophylaxis
Since D+/R− patients are at highest risk for developing late-
onset CMV disease, most studies have targeted this population
in the assessment of immune monitoring for CMV, although
other high-risk patients (lung transplant recipients or patients
receiving T-cell-depleting antibodies) have also been included
in these studies. In a study byKumar et al., patients at high risk
for the development of CMV disease were monitored with the
Quantiferon-CMVassay for the duration of prophylaxis [16].
Patients with a positive result for the assay at the end of
prophylaxis had a lower incidence of late-onset CMV disease
(3.3 % in patients with interferon-γ levels >0.2 IU/ml, as
compared with 21.8 % in patients with a negative response,
p =.04). In D+/R− patients, incidence of CMV disease was
10 % in patients with a detectable CD8+ T-cell response, as
compared with 40 % in patients with no response. In another
study performed in lung transplant recipients, the result of the
Quantiferon-CMV assay predicted the incidence of CMV
viremia (25 % vs. 72 % in patients with a positive, as com-
pared with a negative, result, respectively) [38]. Of note, all 4
patients who eventually developed CMVdisease had a previous
undetectable cell-mediated immune response. Finally, in a re-
cent study involving an international multicenter cohort of 126
D+/R− SOT recipients, the Quantiferon-CMV assay was
performed at the time of discontinuation of antiviral prophylaxis
and two times thereafter [17•]. Patients with a positive assay
had a lower incidence (4 %) of CMV disease than did
patients with a negative result (22 %) and an indeterminate
result (58 %) of the assay (p <.001; see Fig. 1). The
positive predictive value (i.e., protection from CMV disease
in patients with a positive assay) was .93, although because
of low sensitivity, the negative predictive value of the assay
was only moderate (.27).
Taken together, the data from these studies indicate that
D+/R− patients who develop a specific CMV T-cell response
during or after discontinuation of antiviral prophylaxis are
protected against CMV disease. These patients may benefit
from a reduction in the duration of prophylaxis and/or no
additional surveillance. A significant number of patients
with a negative test will never develop CMV disease, so
increasing the sensitivity of cell-mediated immune assays
would be desirable in order to better stratify this group of
patients. Patients with an indeterminate result represent a
highly immunosupressed population at very high risk for
developing CMV disease. These patients will likely benefit
from a reduction in immunosuppression or from prolonged
antiviral prophylaxis.
Monitoring of Preemptive Therapy in Asymptomatic Patients
with CMV Viremia
Cell-mediated immunity assays may also guide the use of
antiviral therapy in patients followed by the preemptive
approach. Because a positive cell-mediated immune response
identifies patients at low risk for CMV disease, the decision to
start antiviral therapy in patients with asymptomatic CMV
DNAemia may be taken according to the result of the immune
assay, thus avoiding the excessive use of antiviral drugs in
patients at low risk for progression to CMV disease. This
approach has been studied in a prospective study involving
37 SOT recipients who were followed by the preemptive
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approach (either early after transplant or after discontinuation
of antiviral prophylaxis) [37]. Most patients (24/26, 92 %)
who had a positive Quantiferon-CMV assay spontaneously
cleared CMV DNAemia without need of antiviral therapy.
On the contrary, patients with a negative Quantiferon-CMV
at the time of CMV DNAemia received more antiviral
therapy (7/11, 63 %). Despite the modest sample size, this
study suggests that antiviral therapy could be safely with-
held in patients with a detectable cell-mediated response to
CMV. An interventional trial integrating immune monitoring
in the management of patients followed by the preemptive
approach is ongoing.
Pretransplant Assessment of Seropositive Patients
Pretransplant CMV serology remains an essential tool for
stratifying the risk of developing CMV disease posttransplant
[1••]. The role of assessing pretransplant cell-mediated immu-
nity status in estimating the risk for CMV replication
posttransplant has been recently analyzed [18, 22]. In a study
of Cantisán et al., the Quantiferon-CMVassay was performed
pretransplant in 55 lung and kidney transplant recipients [18].
In R+ patients, the Quantiferon assay was reactive in only
two thirds of the patients. Interestingly, R+ patients with a
nonreactive Quantiferon-CMV assay had a significant higher
risk for developing posttransplant CMV DNAemia than did
patients with a reactive Quantiferon-CMV (50 % vs. 13 %,
respectively). In addition, all 5 patients who developed CMV
disease had a nondetectable T-cell response. In a study by
Bestard et al., an ELISPOT assay was used at baseline and
6months after transplantation in 137 kidney transplant recipients
[22]. Pretransplant anti-IE-1-specific T-cell responses were sig-
nificantly lower in patients with posttransplant CMV infection,
and they appropriately predicted the risk for CMV replication in
both R+ and D+/R− patients. Overall, the measurement of
pretransplant cell-mediated immunity appears to be an additional
tool for better defining the risk for posttransplant CMVinfection,
irrespectively of the CMV serostatus.
Fig. 1 Kaplan–Meier curves of the incidence of cytomegalovirus (CMV)
disease according to the result of the Quantiferon-CMV assay (log-rank
test, p <.001). See the text for definitions. Used with permission from
Manuel et al. [17•]
Table 1 Potential clinical application of immune monitoring in the management of cytomegalovirus (CMV) after organ transplantation
Clinical scenario Aim of immune monitoring Result of
the assay
Consequence
D+/R− and R+ patients1
During antiviral prophylaxis
After antiviral prophylaxis
During preemptive therapy
To determine the duration of prophylaxis
To determine the risk for developing CMV
disease
To determine the progression to
symptomatic CMV disease
Positive
Negative
Positive
Negative
Positive
Negative
- Stop prophylaxis
- Prolong prophylaxis or close monitoring after
discontinuation of prophylaxis
- No further monitoring
- Close monitoring or reduction of
immunosuppression
- Withhold antiviral therapy2
- Start antiviral therapy
Pretransplant evaluation of R+ patients3 To determine the risk for developing
posttransplant CMV disease
Positive
Negative
- No prevention needed
- Administer prophylaxis/preemptive therapy
In patients post-CMV disease To determine the risk for relapse after
discontinuation of antiviral therapy
Positive
Negative
- No secondary prophylaxis needed
- Administer secondary prophylaxis
In patients receiving anti-rejection therapy
(with T-cell depleting agents)
To determine the risk for developing CMV
disease
Positive
Negative
- No prevention needed
- Administer prophylaxis/preemptive therapy
All of these indications for immune monitoring need validation in interventional trials. Adapted from Kotton et al. [1••]
1 Particularly in patients receiving induction therapy with T-cell-depleting antibodies
2 In D+/R− patients, because of the high risk for progression to CMV disease, even patients with a positive immune assay may require antiviral therapy
3 In patients not receiving T-cell-depleting antibodies
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Future Research
The main conclusion that we can draw from all the recent
experience with the use of immune monitoring for CMV is that
it has an excellent positive predictive value for predicting pro-
tection from CMV disease but that an enhancement of the
sensitivity of the assay would be necessary to improve the
performance of cell-mediated immunity assays in routine clini-
cal practice. Additional studies are needed to assess the perfor-
mance of immune monitoring for CMV in specific clinical
situations, such as the need for antiviral prophylaxis in patients
receiving antirejection therapy, or to predict the relapse of CMV
disease after discontinuation of antiviral therapy (Table 1). In
addition, the relationship between a detectable cell-mediated
immunity against CMVand other transplant outcomes, such as
graft function, has not been evaluated yet. More important, so
far, all the data generated on the use of immunemonitoring have
been extracted from observational studies. We need interven-
tional randomized controlled trials to know the added value of
immune monitoring for CMV in the management of CMV
disease. The availability of new commercial assays, standard-
ized and easy to perform in any transplant center, should facil-
itate the implementation of such interventional studies. Given
the rapidly growing experience with the use of cell-mediated
immunity assays, it can be expected that, similarly to their use in
the diagnosis of latent tuberculosis, immune monitoring may
become part of the standard of care for the prevention of CMV
disease after solid-organ transplantation.
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